Ticagrelor-based therapy for recent mild stroke or high-risk TIA
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether switching to a simpler antiplatelet medication (ticagrelor) after a mild stroke or high-risk TIA can prevent another stroke while reducing the risk of bleeding. It is for people who have not received clot-busting treatment or had a large stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Had a mild stroke within the past 24 hours, or a high-risk TIA (mini-stroke with ABCD score > 4)
- Stroke must be confirmed by CT or MRI brain scan with no large damaged area
- No known cause of stroke from the heart (like atrial fibrillation, low heart pumping function, or valve disease)
- No unusual causes like a torn artery or blood vessel inflammation
- No significant narrowing (more than 50%) of the main neck artery on the affected side
- No history of bleeding in the brain or stomach in the last 6 months, and no current blood disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding aspirin to either ticagrelor or clopidogrel (two antiplatelet medicines) can help prevent another stroke in people who recently had a minor stroke or TIA affecting a large brain artery. It is for people who started antiplatelet treatment within 24 hours of their symptoms.
This trial tests whether adding ticagrelor or cilostazol to aspirin is better than aspirin alone for preventing another stroke. It is for patients who recently had a minor stroke or a transient ischemic attack (TIA) caused by a blockage in a large artery.
This trial tests whether combining aspirin with a second antiplatelet drug (ticagrelor or clopidogrel) helps prevent another stroke after a mild stroke or TIA. It might lower your risk of having another event.
This trial tests whether taking aspirin along with either ticagrelor or cilostazol helps prevent another stroke in people who have had a mild stroke or transient ischemic attack (mini-stroke). You must start treatment within 24 hours of your first symptoms.
This trial tests a new anti-platelet drug called Tiprogrel to prevent another stroke in people who recently had a minor stroke or a transient ischemic attack (TIA) with certain artery narrowing or plaques. It aims to see if this medicine is safe and works better than current treatments.
This study compares two blood thinner medicines, ticagrelor and cilostazol, to see which is better at preventing another stroke in people who have just had a minor stroke or TIA (a mini-stroke). It is for people who started treatment within 24 hours of their symptoms.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.